retatrutide liver benefits (“reta”) is an experimental weight-loss drug currently in Phase 3 clinical trials. It's a once-weekly injection similar to Ozempic and Mounjaro—but more powerful. The reason comes down to how it works Toxicity linked to unapproved peptide

Jrgensen JO, Krag M, Jessen N, Norrelund H, Vestergaard ET, Moller N, et al

Neurology is particularly high stakes: the EVOKE and EVOKE+ Phase 3 trials of semaglutide in early Alzheimers disease, due in 202526, will be the first large-scale cognitive readouts

They found most of these events occurred within the first 4 months of therapy, and skin was the commonly involved site, followed by the gastrointestinal and the endocrine system

These results support a mechanism in which postsynaptic septal GLP-1R activation regulates 2-AG levels to alter presynaptic DA homeostasis and cocaine actions through AA

It helps neutralize harmful free radicals in the body, which are unstable molecules that can cause oxidative stress and damage cells

Standard protocols typically move from 0.25mg to 0.5mg to 1.0mg weekly